Date Filed | Type | Description |
10/13/2023 |
8-K
| Quarterly results |
09/29/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
8-K
| Quarterly results |
05/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which such Loan Party, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time prior to the execution of this Amendment, for or on account of, or in relation to, or in any w..." |
|
05/25/2023 |
4
| JOHNSON SABRINA MARTUCCI (Director) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/25/2023 |
4
| Auerbach Michael (Director) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/25/2023 |
4
| Smiley Andrea Heslin (Director) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/25/2023 |
4
| Camm Jason (Director) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/25/2023 |
4
| Angermayer Christian (10% Owner) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/25/2023 |
4
| Kalali Amir H (Director) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 64,000 options
@ $1.88, valued at
$120.3k
|
|
05/19/2023 |
3
| Johnson Anne Nagengast (Chief Accounting Officer) has filed a Form 3 on ATAI Life Sciences N.V. |
05/17/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Quarterly results |
04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/24/2023 |
8-K
| Quarterly results |
03/16/2023 |
4
| Rao Srinivas (See Remarks) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 600,000 options
@ $1.18, valued at
$708k
Granted 350,000 restricted stock units
@ $0 |
|
03/16/2023 |
4
| Brand Florian (See Remarks) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 1,600,000 options
@ $1.18, valued at
$1.9M
Granted 700,000 restricted stock units
@ $0 |
|
03/16/2023 |
4
| Bardin Stephen (CFO) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 600,000 options
@ $1.18, valued at
$708k
Granted 350,000 restricted stock units
@ $0 |
|
03/16/2023 |
4
| Gutierrez-Esteinou Rolando (Chief Medical Officer) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 500,000 options
@ $1.18, valued at
$590k
Granted 200,000 restricted stock units
@ $0 |
|
03/16/2023 |
4
| Kirpekar Sahil (Chief Business Officer) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 275,000 options
@ $1.18, valued at
$324.5k
Granted 200,000 restricted stock units
@ $0 |
|
02/10/2023 |
SC 13G/A
| Apeiron Investment Group Ltd. reports a 19.4% stake in ATAI Life Sciences N.V. |
12/02/2022 |
4
| Kirpekar Sahil (Chief Business Officer) has filed a Form 4 on ATAI Life Sciences N.V.
Txns:
| Granted 750,000 options
@ $3.34, valued at
$2.5M
|
|
12/02/2022 |
3
| Kirpekar Sahil (Chief Business Officer) has filed a Form 3 on ATAI Life Sciences N.V. |
11/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
10/14/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
09/19/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
09/09/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
08/17/2022 |
3
| Bardin Stephen (CFO) has filed a Form 3 on ATAI Life Sciences N.V. |
08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|